News articles about Egalet Corporation (NASDAQ:EGLT) have trended positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Egalet Corporation earned a media sentiment score of 0.31 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 50 out of 100, meaning that recent press coverage is somewhat likely to have an impact on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s analysis:
- Traders Keeping Egalet Corp (EGLT) on Close Watch As Shares Move – Sparta Review (spartareview.com)
- Comparing Price Charts: PTC Therapeutics, Inc. (PTCT), Egalet Corporation (EGLT) – StockNewsMagazine (stocknewsmagazine.com)
- Bounding Shares, What’s Next for Egalet Corporation (NASDAQ:EGLT)? – FLBC News (flbcnews.com)
- A Look at Price Fluctuation of Egalet Corporation (EGLT) (ismboard.com)
- Egalet Corporation (NASDAQ:EGLT) Getting Somewhat Positive Press Coverage, Report Finds (healthcaremenu.net)
Shares of Egalet Corporation (EGLT) traded down 0.69% during midday trading on Tuesday, reaching $1.43. 44,108 shares of the company traded hands. The stock has a 50 day moving average price of $2.60 and a 200 day moving average price of $4.60. Egalet Corporation has a 1-year low of $1.32 and a 1-year high of $10.00. The firm’s market capitalization is $35.80 million.
Egalet Corporation (NASDAQ:EGLT) last announced its quarterly earnings data on Wednesday, May 10th. The specialty pharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.12. The company had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $6.92 million. Egalet Corporation had a negative net margin of 494.00% and a negative return on equity of 607.49%. During the same quarter in the previous year, the business posted ($0.76) EPS. Analysts expect that Egalet Corporation will post ($3.52) earnings per share for the current fiscal year.
A number of equities analysts have commented on EGLT shares. Cantor Fitzgerald set a $8.00 price target on shares of Egalet Corporation and gave the company a “buy” rating in a research report on Saturday, May 13th. Zacks Investment Research raised shares of Egalet Corporation from a “hold” rating to a “buy” rating and set a $3.50 price objective on the stock in a research report on Tuesday, May 9th. JMP Securities dropped their price target on shares of Egalet Corporation from $15.00 to $6.00 and set a “market outperform” rating on the stock in a report on Friday. ValuEngine downgraded shares of Egalet Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Gabelli raised shares of Egalet Corporation from a “hold” rating to a “buy” rating and set a $9.50 price objective on the stock in a report on Friday, May 12th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $10.20.
ILLEGAL ACTIVITY WARNING: “Egalet Corporation (NASDAQ:EGLT) Receives News Impact Score of 0.31” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/07/18/egalet-corporation-eglt-earning-favorable-press-coverage-accern-reports-updated-updated.html.
Egalet Corporation Company Profile
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.